Martingale Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Martingale Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$527K	Buy	41,763 +4,710	+13%	+$54K	0.01%	624
2025 Q4	$381K	Hold	37,053	–	–	0.01%	652
2025 Q3	$215K	Sell	37,053 -2,410	-6%	-$14.1K	0.01%	734
2025 Q2	$265K	Sell	39,463 -700	-2%	-$5.63K	0.01%	723
2025 Q1	$363K	Buy	40,163 +1,540	+4%	+$19.2K	0.01%	651
2024 Q4	$668K	Buy	38,623 +700	+2%	+$12.7K	0.02%	557
2024 Q3	$606K	Buy	37,923 +10,226	+37%	+$161K	0.01%	590
2024 Q2	$395K	Buy	27,697 +9,245	+50%	+$131K	0.01%	651
2024 Q1	$261K	Buy	+18,452	New	+$261K	0.01%	728

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's TRDA Position: Q1 2026 in Review

Martingale Asset Management increased its Entrada Therapeutics (TRDA) stake by 13% in Q1 2026, buying an estimated $54K and bringing the position to 41,763 shares worth $527K. The position accounts for 0.01% of the portfolio, ranked #624.

Martingale Asset Management first reported a position in TRDA in Q1 2024 and has held it in 9 quarters since. The position peaked at $668K in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Martingale Asset Management held 41,763 shares of Entrada Therapeutics worth $527K as of Q1 2026.
Martingale Asset Management bought 4,710 Entrada Therapeutics shares in Q1 2026, an estimated $54K.
Entrada Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #624 holding.
Martingale Asset Management first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 9 quarters since.
Martingale Asset Management's Entrada Therapeutics position peaked at $668K in Q4 2024.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.